AOD-9604 vs Retatrutide
AOD-9604 is a synthetic hexadecapeptide corresponding to the C-terminal lipolytic domain of human growth hormone, usually written as hGH fragment 176-191, and its literature was built between 1993 and 2001 on rodent obesity models, then extended by a pooled human safety analysis and a non-clinical toxicology package assembled to support use as a food ingredient. Retatrutide is an investigational single peptide that agonises the GIP, GLP-1 and glucagon receptors, characterised from 2022 onward in phase 1 and phase 2 randomised trials and, from 2026, in the first published phase 3 readout. The two are paired constantly in vendor comparison pages and stacking articles, and not once in the scientific record: no publication indexed in PubMed or Europe PMC names both compounds, in the abstract or in the full text. Every comparison below is therefore indirect, drawn from separate literatures that differ in era, design and endpoint.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study has administered AOD-9604 and retatrutide together, compared them, or even discussed them in the same publication. Searches of PubMed by drug name, development code and sequence description, and of Europe PMC across full text, returned no record naming both; a strict query pairing the two returns nothing, and broadening the second term to the triple-agonist class does not change that. The closest records run in one direction only: obesity-pipeline reviews from the 2000s and 2010s that listed AOD-9604 alongside early incretin-based agents, all published years before retatrutide was first described, and recent narrative reviews of peptides used outside regulated supply that cover AOD-9604 without mentioning retatrutide at all. Because no paper engages both compounds, this page lists no head-to-head studies rather than presenting class-level reviews as if they compared the two. What follows is a comparison of two separate evidence bases: one that peaked more than two decades ago and never produced a published efficacy trial, and one that is currently generating phase 3 data.
Side by side.
| AOD-9604 | Retatrutide | |
|---|---|---|
| Evidence maturity | Early clinical | Clinical |
| Studies cited here | 17 | 15 |
| Published 2023 or later | 4 | 13 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A 16-amino-acid synthetic fragment reproducing the C-terminal lipolytic domain of human growth hormone. It was isolated from work asking which part of the hormone carried the fat-metabolism activity, and the fragment was developed as a molecule separable from the hormone's growth-promoting effects. | A single synthetic peptide engineered to agonise three receptors at once: GIP, GLP-1 and glucagon. It was designed rather than derived, and the discovery paper described balanced activity at all three receptors as the intended property. |
| Mechanism as described in the literature | Increased lipolytic and reduced lipogenic activity in adipose tissue, with fat oxidation raised in obese rodents. Binding experiments indicated no interaction with the growth hormone receptor, and effects persisted in beta3-adrenergic receptor knock-out animals, so the pathway was not attributed to that receptor. | Combined incretin and glucagon receptor signalling. Published work attributes weight reduction to lower energy intake together with increased energy expenditure, with appetite ratings falling as exposure rises and glycaemic effects mediated through the incretin arms. |
| Size of the evidence base | Small and largely historical. Six preclinical papers between 1993 and 2001 define the pharmacology; the remainder of the record is a pooled human safety analysis, a non-clinical toxicology and genotoxicity package, one rabbit osteoarthritis study, anti-doping analytical chemistry and narrative reviews. | Large and current. Phase 1b, three phase 2 randomised trials in obesity, type 2 diabetes and steatotic liver disease, substudies on body composition, kidney parameters, appetite and cardiovascular biomarkers, a systematic review and meta-analysis, phase 3 design papers and one published phase 3 result. |
| Best-characterised finding | Reduced body-weight gain in genetically obese and diet-induced obese rodents, reported in one chronic oral study as a fall of more than half relative to controls, accompanied by increased fat oxidation. Equivalent findings in humans were never published as a standalone efficacy report. | Dose-dependent weight reduction in a 48-week phase 2 obesity trial, where the least-squares mean change in body weight was -24.2% at the highest dose against -2.1% with placebo. A substudy quantified how much of that change came from fat mass rather than lean tissue. |
| Human data | Limited to safety and tolerability. Six randomised, double-blind, placebo-controlled trials were pooled in a single 2013 report, which found no effect on serum IGF-1, no negative effect on oral glucose tolerance and a tolerability profile indistinguishable from placebo. No body-composition efficacy trial has appeared in an indexed journal. | Extensive and efficacy-focused. Randomised placebo-controlled trials with weight, HbA1c, liver fat, body composition, renal and lipid endpoints, an active dulaglutide comparator in type 2 diabetes, and a 2026 phase 3 trial in 537 adults reporting HbA1c reductions against placebo. |
| Evidence maturity | Early clinical and stalled. The development programme produced human safety data but no published efficacy trial, and the primary research on the compound itself effectively ended in the 2000s; work published since is analytical, orthopaedic or review material. | Late clinical and active. A registrational phase 3 programme in obesity, sleep apnoea and knee osteoarthritis has published rationale and design papers, a separate programme addresses type 2 diabetes and chronic kidney disease, and the first phase 3 efficacy readout is now in print. |
| Safety signals reported | Nothing serious in the published record, and little of it. Genotoxicity assays were negative, chronic oral administration in rats and monkeys was reported as generally safe, and the pooled human analysis detected no anti-drug antibodies in the participants assayed. Long-term and injectable human exposure remain unaddressed. | Predominantly gastrointestinal and related to escalating exposure, reported consistently across the phase 2 trials and the systematic review. Long-term safety, cardiovascular outcomes and what happens after discontinuation have not been established in published reports. |
| Regulatory status | Not an approved medicine anywhere. The non-clinical package was assembled to support a food-ingredient position rather than a drug approval, and the compound is prohibited in sport, with urinary detection methods and a stable metabolite proposed for longer detection windows. | Investigational and unapproved in every jurisdiction as of August 2026, with phase 3 trials ongoing and sponsor announcements of topline results preceding peer-reviewed publication. |
And what it does not.
The evidence bases are not merely unequal in size, they are unequal in kind. Retatrutide has randomised, placebo-controlled human trials reporting the outcomes people actually care about, weight, glycaemia, liver fat and body composition, with an active comparator in one trial and a first phase 3 result now published. AOD-9604 has a coherent rodent story about fat metabolism, a pooled human safety analysis showing it did not raise IGF-1 or disturb glucose tolerance, and no published efficacy trial in people at all, which is why its research entry describes body-composition outcomes as unreplicated in the indexed literature. That asymmetry does not make retatrutide the safer choice: it is unapproved, its long-term safety and cardiovascular outcomes are unpublished, its gastrointestinal adverse events are consistent across trials, and durability after stopping has not been reported. Nor does it make AOD-9604 the gentler option, since absence of adverse findings in a small safety dataset is not the same as an established safety profile. Because nothing has compared them, no published basis exists for stating that either produces more fat loss than the other.
Common questions.
- Has any published study compared AOD-9604 with retatrutide?
No. Searches of PubMed using drug names, the development code LY3437943 and the sequence description hGH fragment 176-191, together with full-text searches of Europe PMC, returned no publication that names both compounds. There is no comparative trial, no shared review and not even an incidental co-mention. Every side-by-side ranking of the two currently circulating comes from vendor and aggregator pages rather than from the scientific record.
- Why has AOD-9604 never had a published efficacy trial in humans?
The compound did enter human obesity trials, and their pooled safety and tolerability data were published in 2013, but the efficacy results were never issued as a standalone peer-reviewed report. The subsequent published record moved toward a non-clinical toxicology package supporting use as a food ingredient, anti-doping analytical methods and narrative reviews. As a result, the body-composition claims made for the compound rest on rodent studies and on data that has not been independently replicated in an indexed journal.
- What did the pooled human safety analysis of AOD-9604 actually show?
It combined six randomised, double-blind, placebo-controlled trials using intravenous and oral administration, including cohorts of adults with obesity. Serum IGF-1 was unaffected and oral glucose tolerance testing showed no negative effect on carbohydrate metabolism, which contrasted with intact growth hormone. No anti-AOD9604 antibodies were detected among the participants selected for antibody assay, and the tolerability profile was reported as indistinguishable from placebo. The analysis addressed safety rather than whether the compound reduced fat.
- How mature is the retatrutide evidence base at present?
It spans discovery pharmacology through phase 3. Phase 2 randomised trials covered obesity over 48 weeks, type 2 diabetes with a dulaglutide comparator, and steatotic liver disease, with substudies on body composition, kidney parameters, appetite and cardiovascular biomarkers. Design papers describe a four-trial registrational programme and a separate chronic kidney disease trial, and a phase 3 trial in adults with type 2 diabetes was published in 2026. The compound remains unapproved everywhere.
- Do the two compounds act on the same biology?
The published mechanisms do not overlap. Work on the growth hormone fragment describes direct effects on adipose tissue, increasing lipolytic and reducing lipogenic activity, with binding experiments indicating no interaction with the growth hormone receptor. Retatrutide acts on three peptide hormone receptors, and its published effects run through reduced energy intake and increased energy expenditure, with appetite and eating-behaviour endpoints measured directly in a phase 2 trial. No study has examined whether the two pathways interact.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.